Want to see PULM full AI Analyst Report?
PULM Stock Chart & Stats
$1.52
$0.08(4.85%)
At close: 4:00 PM EDT
$1.52
$0.08(4.85%)
Day’s Range― - ―
52-Week Range$1.16 - $5.50
Previous Close$1.69
Volume9.13K
Average Volume (3M)21.74K
Market Cap
$5.15M
Enterprise Value$4.31
Total Cash (Recent Filing)$2.17M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding3,652,285
10 Day Avg. Volume41,569
30 Day Avg. Volume21,736
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$16.45M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of reported debt removes interest expense and reduces refinancing pressure, giving the company more flexibility than a similarly loss-making business with leverage. This supports balance-sheet resilience over the next several months, although it does not eliminate funding needs.
Reduced Cash BurnThe substantial reduction in operating cash burn indicates improved cost discipline or lower spending relative to earlier periods. If maintained, this could extend financial runway and reduce the frequency or size of external financing required while the company advances its pipeline.
Proprietary Inhaled PlatformA proprietary lung-delivery technology provides a differentiated foundation for developing multiple respiratory candidates rather than relying on a single asset. The platform can support partnering and potential royalty opportunities if clinical development and commercialization succeed.
Bears Say
No Current Revenue BaseEffectively zero revenue means the company has not yet demonstrated a recurring commercial engine to support operations. Continued losses without product or partnership revenue leave future progress dependent on successful development, licensing, or eventual commercialization.
Severely Reduced Equity CushionThe steep decline in stockholders’ equity reflects substantial cumulative value erosion and leaves a much smaller financial cushion than in prior years. This reduces the company’s ability to absorb setbacks and increases the strategic importance of securing funding or monetizing assets.
Persistent Cash ConsumptionAlthough cash burn has improved, the business continues to consume cash and free cash flow remains negative. Without a positive operating base, ongoing research and development must be funded externally or through partnering, creating a durable constraint on execution.
Pulmatrix News
PULM FAQ
What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was $1.16 and its highest was $5.50 in the past 12 months.
What is Pulmatrix’s market cap?
Pulmatrix’s market cap is $5.15M.
When is Pulmatrix’s upcoming earnings report date?
Pulmatrix’s upcoming earnings report date is Nov 05, 2026 which is in 53 days.
How were Pulmatrix’s earnings last quarter?
Pulmatrix released its earnings results on Aug 13, 2026. The company reported -$0.288 earnings per share for the quarter.
Is Pulmatrix overvalued?
According to Wall Street analysts Pulmatrix’s price is currently Overvalued.
Does Pulmatrix pay dividends?
Pulmatrix does not currently pay dividends.
What is Pulmatrix’s EPS estimate?
Pulmatrix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pulmatrix have?
Pulmatrix has 3,652,285 shares outstanding.
What happened to Pulmatrix’s price movement after its last earnings report?
Pulmatrix reported an EPS of -$0.288 in its last earnings report. Following the earnings report the stock price went down -6.211%.
Which hedge fund is a major shareholder of Pulmatrix?
Currently, no hedge funds are holding shares in PULM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pulmatrix
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
1.84% Mutual Funds
0.52% Other Institutional Investors
96.76% Public Companies and
Individual Investors